With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage – AJMC.com Managed Markets Network
|
With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage
AJMC.com Managed Markets Network The first CAR T-cell therapy, tisagenlecleucel (Kymriah)—a treatment for children and young adults with B-cell acute lymphoblastic leukemia (ALL) developed by Novartis—was priced at $475,000 for a one-time treatment.3 Axicabtagene ciloleucel … Undervalued And Attractive: Pick Up Novartis In 2018 |
